Daily OCS dose reduction
Trial 3 primary endpoint: Patients treated with NUCALA achieved greater reductions in daily OCS dose (Weeks 20 to 24) while maintaining asthma control vs placebo (P=0.008).1
CI=confidence interval; ICS=inhaled corticosteroid;
OCS=oral corticosteroid; SOC=standard of care.
CI=confidence interval; ICS=inhaled corticosteroid;
OCS=oral corticosteroid; SOC=standard of care.
In a controlled OCS reduction study (Trial 3), 14% of patients treated with NUCALA vs 8% treated with placebo eliminated daily OCS use while maintaining asthma control.1
Real-World Study Interim Analysis2: Associated with discontinuation of maintenance OCS
Results are descriptive. Weeks 53-56 (n=125).
Real-World Study Limitations: Prespecified interim analysis of a single-arm, prospective, observational cohort study; may not reflect results from final dataset.
Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.